The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
In this video, Gloria Iacoboni, MD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, gives an overview of novel immunotherapy approaches in lymphoma, including CAR-T cells and bispecific antibodies. Dr Iacoboni highlights the encouraging results which have been observed with the use of these agents, and further comments on the optimal sequencing of these therapies. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria and travel support: Novartis, Kite/Gilead, Bristol-Myers Squibb, Abbvie, Autolus, Sandoz, Miltenyi, AstraZeneca.
